Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Network of Cancer Drug Repositories Improves Access to Treatment, Reduces Waste

Federally Funded Clinical Trials Play a Vital Role in Cancer Research, Especially for Rare and Pediatric Cancers

Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress

Breast Volume Preservation Comparable After Five-Fraction Whole- or Partial-Breast Radiotherapy

Genetic Modification of the AJCC Classification for Papillary Thyroid Cancer